Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P57059
UPID:
SIK1_HUMAN
Alternative names:
Salt-inducible kinase 1; Serine/threonine-protein kinase SNF1-like kinase 1
Alternative UPACC:
P57059; A6NC84; Q5R2V5; Q6ZNL8; Q86YJ2
Background:
Serine/threonine-protein kinase SIK1, also known as Salt-inducible kinase 1, plays a pivotal role in cell cycle regulation, gluconeogenesis, lipogenesis, muscle growth, and tumor suppression. It phosphorylates a range of substrates including HDAC4, HDAC5, and SREBF1, influencing CREB activity and sodium-sensing signaling pathways. Its involvement in cardiomyogenesis and hepatic metabolism underscores its regulatory significance in cellular processes.
Therapeutic significance:
SIK1's link to Developmental and epileptic encephalopathy 30, a severe early-onset epilepsy, highlights its potential as a therapeutic target. Understanding SIK1's role could pave the way for innovative treatments for this and possibly other neurodevelopmental disorders.